pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['kn671', 'nsclc', 'pembro', 'sclc']
#asco23 kn671 ph iii neoadj chemo-pembro + 1 yr adjuvant io in early stage nsclc - screened &gt;1300pts
- 84%pts completed 3 neoadj cycles, 75% 4 cycles - efs hr 0.58. - pcr 18 v 4%
- os data not mature, but curves separate wowsers 
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University